Ceftolozane/Tazobactam for Complex and Resistant Infections: Systematic Reviews of Comparative Efficacy Studies.

Area of Science:

• Infectious Diseases
• Pharmacology
• Clinical Medicine

Background:

• Multidrug-resistant (MDR) infections pose significant clinical and economic challenges.
• Novel therapeutic strategies are crucial to combat the rise of MDR pathogens.
• Ceftolozane/tazobactam offers a potential treatment targeting MDR organisms.

Purpose of the Study:

• To evaluate the comparative efficacy of ceftolozane/tazobactam.
• Assess efficacy across complex intra-abdominal infections, complex urinary tract infections, and hospital-acquired/ventilator-associated pneumonia.
• Determine outcomes including mortality, clinical cure, and microbiological eradication.

Main Methods:

• Conducted two systematic literature reviews.
• Included randomized controlled trials comparing ceftolozane/tazobactam with other interventions.
• Focused on specific infection indications and key clinical outcomes.

Main Results:

• Ceftolozane/tazobactam demonstrated non-inferiority to comparators for all assessed outcomes.
• Non-inferiority in all-cause mortality was observed compared to meropenem.
• Clinical cure and microbiological eradication rates were non-inferior to meropenem or levofloxacin.

Conclusions:

• Ceftolozane/tazobactam is a supported alternative, especially for suspected or documented MDR pathogens.
• Findings may aid in standardizing treatment guidelines for complex infections.
• Potential to reduce the clinical and economic burden of MDR infections.